Trial 0S-16-18


A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Type: Treatment
Phase: Phase I
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic, Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Cristina De Leon, Coordinator, Lorraine Martinez, Coordinator, Fahim Raian, D.M., Nicole Jensen, Coordinator, Rishi Bhavsar, Coordinator, Marisabel Hurtado Castillo, Coordinator, Jiayi Jiang, D.M., Anayansi Miloud, D.M., Jessica Levano, Coordinator, Taison Tran, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Rabia Rehman, Coordinator, Atessa Kiani, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.